{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myopathy%3B+Hereditary&page=2",
    "query": {
      "condition": "Myopathy; Hereditary",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myopathy%3B+Hereditary&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T04:41:46.037Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01784679",
      "title": "GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Inclusion Body Myopathy",
        "GNE Myopathy",
        "Nonaka Disease",
        "Quadriceps Sparing Myopathy (QSM)",
        "Distal Myopathy With Rimmed Vacuoles (DMRV)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 319,
      "start_date": "2013-04-05",
      "completion_date": "2017-11-30",
      "has_results": false,
      "last_update_posted_date": "2018-04-27",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01784679"
    },
    {
      "nct_id": "NCT00005574",
      "title": "Gentamicin Treatment of Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Becker Muscular Dystrophy",
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Gentamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 4,
      "start_date": "2000-02",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005574"
    },
    {
      "nct_id": "NCT02895789",
      "title": "Oxidative Capacity and Exercise Tolerance in Ambulatory SMA",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Muscular Atrophy Type 3",
        "Mitochondrial Myopathy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "8 Years to 55 Years"
      },
      "enrollment_count": 42,
      "start_date": "2016-11",
      "completion_date": "2021-01",
      "has_results": false,
      "last_update_posted_date": "2022-03-08",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02895789"
    },
    {
      "nct_id": "NCT01826487",
      "title": "Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophies",
        "Muscular Disorders, Atrophic",
        "Muscular Diseases",
        "Musculoskeletal Diseases",
        "Neuromuscular Diseases",
        "Nervous System Diseases",
        "Genetic Diseases, X-Linked",
        "Genetic Diseases, Inborn"
      ],
      "interventions": [
        {
          "name": "Ataluren",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PTC Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "16 Years",
        "sex": "MALE",
        "summary": "7 Years to 16 Years · Male only"
      },
      "enrollment_count": 230,
      "start_date": "2013-03-26",
      "completion_date": "2015-08-20",
      "has_results": true,
      "last_update_posted_date": "2020-08-04",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 17 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gulf Breeze",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01826487"
    },
    {
      "nct_id": "NCT04886518",
      "title": "Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy 1",
        "Excessive Daytime Sleepiness"
      ],
      "interventions": [
        {
          "name": "Pitolisant Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harmony Biosciences Management, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2021-06-28",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-04-25",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 11,
      "location_summary": "Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886518"
    },
    {
      "nct_id": "NCT00518817",
      "title": "The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Muscular Dystrophy",
        "Dilated Cardiomyopathy",
        "Heart Failure"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "1 Month to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-08",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2007-08-21",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00518817"
    },
    {
      "nct_id": "NCT07642635",
      "title": "Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)"
      ],
      "interventions": [
        {
          "name": "Semaglutide (Rybelsus®)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2026-09-01",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07642635"
    },
    {
      "nct_id": "NCT03558958",
      "title": "Safety and Efficacy of P-188 NF in DMD Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "P-188 NF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phrixus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "25 Years",
        "sex": "MALE",
        "summary": "12 Years to 25 Years · Male only"
      },
      "enrollment_count": 2,
      "start_date": "2018-08-08",
      "completion_date": "2021-09-01",
      "has_results": false,
      "last_update_posted_date": "2023-01-11",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03558958"
    },
    {
      "nct_id": "NCT02766985",
      "title": "Rasch-analysis of Clinical Severity in FSHD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Facioscapulohumeral Muscular Dystrophy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2016-03",
      "completion_date": "2017-04-18",
      "has_results": false,
      "last_update_posted_date": "2018-04-12",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 2,
      "location_summary": "Kansas City, Kansas • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02766985"
    },
    {
      "nct_id": "NCT01388764",
      "title": "Safety, Tolerability and Effects of L-Arginine in Boys With Dystrophinopathy on Corticosteroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dystrophinopathy",
        "Duchenne Muscular Dystrophy",
        "Becker's Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "L-arginine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "11 Years",
        "sex": "MALE",
        "summary": "7 Years to 11 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2012-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2012-07-03",
      "last_synced_at": "2026-07-23T04:41:46.037Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01388764"
    }
  ]
}